Francesca J Torriani
Affiliation: University of California
- Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatmentEdward R Cachay
Department of Medicine, University of California at San Diego, 200 West Arbor Drive, San Diego, California 92103, USA
AIDS Res Ther 8:29. 2011..We aimed to determine the reliability and validity of a hepatitis symptom inventory and to identify predictors of hepatitis C (HCV) treatment initiation in a cohort of HIV-infected patients...
- Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152sFrancesca J Torriani
Infection Prevention and Clinical Epidemiology Unit, University of California San Diego, 200 West Arbor Drive, MC 8951, San Diego, California 92103, USA
J Am Coll Cardiol 52:569-76. 2008..This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial...
- Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfectionFrancesca J Torriani
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, California 92103, USA
J Infect Dis 188:1498-507. 2003..Although the early viral kinetics of coinfected subjects treated with PEG-IFN or IFN differ from those of singly infected subjects, the treatment response seems unaffected...
- Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsFrancesca J Torriani
Department of Medicine, Division of Infectious Diseases, University of California, San Diego, Antiviral Research Center, CA 92103, USA
N Engl J Med 351:438-50. 2004....
- Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infectionGregory J Dore
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
AIDS 21:1555-9. 2007..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
- Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitisRachel D Schrier
Division of Infectious Diseases, Department of Pathology, University of California San Diego, UCSD Medical Center, MC 8416, 200 W Arbor Drive, San Diego, CA 92103 8416, USA
Retina 26:165-9. 2006....
- Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfectionMilos Opravil
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
J Acquir Immune Defic Syndr 47:36-49. 2008..The impact of baseline CD4 status on hepatitis C virus (HCV) treatment response among patients with HIV/HCV coinfection was investigated using data from a randomized study of peginterferon alfa-2a (40KD) + ribavirin (Peg-IFN/RBV)...
- Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger
The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
J Clin Virol 36:283-91. 2006..The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective...
- Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapyStefan Mauss
Center for HIV and Hepatogastroenterology, Dusseldorf, Germany
AIDS 18:F21-5. 2004..This paper identifies risk factors associated with hepatic decompensation in APRICOT...
- Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infectionsFrancesca J Torriani
ACP J Club 142:A12; author reply A13. 2005
- Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposureJudith S Currier
Center for Clinical AIDS Research and Education, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA
AIDS 19:927-33. 2005..The impact of HIV infection and exposure to antiretroviral therapy on the development of subclinical atherosclerosis is incompletely understood...
- A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitisJacob Lalezari
Quest Clinical Research, San Francisco, California 94115, USA
J Acquir Immune Defic Syndr 30:392-400. 2002..Other than a higher than expected frequency of oral candidiasis (17%), no clinical toxicities or laboratory abnormalities occurred during treatment with valganciclovir that have not been observed during treatment with ganciclovir...
- Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infectionBruno R Cotter
Division of Cardiovascular Medicine, Department of Medicine, University of California, San Diego, CA 92103 8411, USA
Cardiovasc Toxicol 4:281-6. 2004..Multicenter, randomized trials using either technique may provide more information about whether HIV infection alone, long-term HAART use, or both may increase the risks of or accelerate coronary disease in HIV-infected patients...
- A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study TeamJudith A Aberg
Department of Medicine, Division of Infectious Disease, University of California San Francisco, San Francisco, CA, USA
J Infect Dis 187:1046-52. 2003..44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART...
- Progression of carotid artery intima-media thickening in HIV-infected and uninfected adultsJudith S Currier
Center for Clinical AIDS Research and Education, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA
AIDS 21:1137-45. 2007..To compare the rate of change in intima-media thickness (IMT) of the carotid artery among uninfected subjects and HIV-infected subjects receiving or not receiving protease inhibitor (PI) regimens over a 144 week period...
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionRichard K Sterling
Section of Hepatology, Virginia Commonwealth University Health System, Richmond, VA 23298 0341, USA
Hepatology 43:1317-25. 2006..In conclusion, noninvasive tests can accurately predict hepatic fibrosis and may reduce the need for liver biopsy in the majority of HIV/HCV-coinfected patients...
- Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adultsWm Christopher Mathews
Department of Medicine, University of California, San Diego, Owen Clinic, UCSD Medical Center, San Diego, CA 92103, USA
J Acquir Immune Defic Syndr 40:155-60. 2005..This study's purpose was to estimate trends in the incidence of and risk factors for clinically significant MRSA (CS-MRSA) infection in a cohort of HIV-infected adults...
- Long-term results of treatment of macular complications in eyes with immune recovery uveitis using a graded treatment approachMohamed H El-Bradey
Shiley Eye Center, San Diego, CA 92093 0946, USA
Retina 24:376-82. 2004..To evaluate the results of a graded treatment approach in a cohort of eyes with macular complications of immune recovery uveitis...
- A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087Judith A Aberg
AIDS Clinical Trials Unit, Bellevue Hospital Center, New York University, New York, New York 10016, USA
AIDS Res Hum Retroviruses 21:757-67. 2005..Combination therapy with fenofibrate and pravastatin for HIV-related dyslipidemia provides substantial improvements in lipid parameters and appears safe, but is unlikely to achieve all NCEP targets for lipid levels...
- Response to: 'carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients'Judith S Currier
AIDS 20:311. 2006